Vertex Pharmaceuticals Inc / Ma
A global biotech developing transformative medicines for serious diseases, Vertex Pharmaceuticals is best known for its cystic fibrosis franchise — KALYDECO, ORKAMBI, SYMDEKO, TRIKAFTA, and ALYFTREK — which treats most people with CF in key Western markets. The company also makes CASGEVY, a CRISPR gene-editing therapy for sickle cell disease and beta thalassemia, and JOURNAVX, a non-opioid pain signal inhibitor for acute pain. Its pipeline targets kidney disease, chronic pain, and type 1 diabetes.
Granted 340.6K · Bought 10.0K · Sold 162.5K
Granted 164.4K · Sold 84.3K
Granted 210.3K · Sold 84.7K
Granted 132.5K · Sold 59.9K
Granted 115.1K · Sold 44.3K
Granted 57.4K · Bought 5.0K · Sold 57.4K
Granted 419.3K · Sold 347.1K
Granted 147.8K · Sold 90.1K
Granted 53.2K · Sold 30.9K
Granted 8.9K · Sold 8.8K
Granted 54.0K · Sold 25.0K
Granted 110.5K · Sold 72.3K
Granted 45.0K · Sold 17.1K
Granted 11.8K · Sold 10.0K
Granted 1.5K
Granted 2.6K · Sold 6.3K
Granted 25.4K · Sold 11.4K
Granted 10.7K · Sold 10.0K
Granted 4.4K · Sold 2.7K
Granted 9.2K · Sold 9.5K
Granted 5.4K
Granted 40.0K · Sold 40.0K
Granted 2.2K
Granted 2.5K
Granted 4.5K
Granted 1.1K
Granted 15.0K · Sold 15.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Kewalramani ReshmaCEO & President, Director · 66 transactions | +43.7% | 106.0K | 340.6K | 10.0K | 162.5K |
| Sachdev AmitEVP Chief Patient & Ext Af Off · 56 transactions | +35.9% | 65.8K | 164.4K | — | 84.3K |
| Arbuckle Stuart AEVP, COO · 85 transactions | +54% | 63.5Kas of Jul 2025 | 210.3K | — | 84.7K |
| Wagner Charles F JrEVP, CO & FO · 81 transactions | +35.6% | 47.0K | 132.5K | — | 59.9K |
| Tatsis OuraniaEVP, Chief Reg. & Quality Off. · 93 transactions | +48.8% | 46.8K | 115.1K | — | 44.3K |
| Sachs Bruce IDirector · 19 transactions | +9.2% | 45.0Kas of Aug 2025 | 57.4K | 5.0K | 57.4K |
| Leiden Jeffrey MExecutive Chairman, Director · 74 transactions | -29.7% | 35.2K | 419.3K | — | 347.1K |
| Altshuler DavidEVP, Chief Scientific Officer · 113 transactions | +2.6% | 34.5K | 147.8K | — | 90.1K |
| Sanna BastianoEVP, Cell & Genetic Therapies · 73 transactions | -3.9% | 32.0Kas of May 2023 | 53.2K | — | 30.9K |
| Liu JoyEVP and Chief Legal Officer · 28 transactions | +141.8% | 20.0K | 8.9K | — | 8.8K |
| Atkinson Edward Morrow IIIEVP, Chief Technical Ops. Off. · 36 transactions | — | 18.4K | 54.0K | — | 25.0K |
| Bozic CarmenEVP and CMO · 57 transactions | -53.5% | 15.3K | 110.5K | — | 72.3K |
| Biller JonathanEVP and Chief Legal Officer · 31 transactions | — | 13.7K | 45.0K | — | 17.1K |
| McKechnie DuncanEVP, Chief Commercial Officer · 11 transactions | — | 12.5K | 11.8K | — | 10.0K |
| Garber Alan MDirector · 3 transactions | +24.7% | 7.3K | 1.5K | — | — |
| Bunnage Mark E.EVP, Chief Scientific Officer · 10 transactions | — | 7.3K | 2.6K | — | 6.3K |
| Ambrose KristenSVP & Chief Accounting Officer · 44 transactions | +375.2% | 6.6K | 25.4K | — | 11.4K |
| Kearney Terrence CDirector · 3 transactions | +12.5% | 6.5Kas of Aug 2023 | 10.7K | — | 10.0K |
| Carney LloydDirector · 8 transactions | +16.9% | 6.3K | 4.4K | — | 2.7K |
| Bhatia Sangeeta N.Director · 43 transactions | -5.1% | 4.9K | 9.2K | — | 9.5K |
| McKenzie DianaDirector · 10 transactions | -3% | 3.4K | 5.4K | — | — |
| Lee YuchunDirector · 79 transactions | +44.2% | 3.3Kas of Jan 2023 | 40.0K | — | 40.0K |
| Schneider JenniferDirector · 4 transactions | — | 2.2K | 2.2K | — | — |
| Thornberry NancyDirector · 5 transactions | — | 2.1K | 2.5K | — | — |
| Upadhyay SuketuDirector · 7 transactions | — | 1.6K | 4.5K | — | — |
| Lagarde MichelDirector · 1 transaction | — | 1.1Kas of Oct 2023 | 1.1K | — | — |
| McGlynn Margaret GDirector · 13 transactions | -83.8% | 178as of May 2022 | 15.0K | — | 15.0K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -1.17M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.